Allergan licenses poly(2-3)Glucose™ for the eye

January, 2015. Allergan, Inc. (NYSE: AGN) purchased an exclusive license from TRGel, LLC for poly(2-3)glucose™ in ophthalmic applications.

LEAVE A COMMENT

Your email address will not be published. Required fields are marked *